Definition And Operational Timepoints
- Status Epilepticus (SE) is defined by the failure of endogenous mechanisms responsible for seizure termination or the initiation of mechanisms that lead to abnormally prolonged seizures.
- The ILAE and updated IAP guidelines utilize a two-timepoint conceptual framework ($t_1$ and $t_2$):
| Operational Timepoint | Convulsive SE (Bilateral Tonic-Clonic) | Focal SE With Impaired Awareness | Absence Status Epilepticus |
|---|---|---|---|
| $t_1$ (Initiate Treatment) | 5 minutes | 10 minutes | 10 to 15 minutes |
| $t_2$ (Neuronal Injury Threshold) | 30 minutes | >60 minutes | Unknown |
- $t_1$ (5 minutes): The time beyond which a seizure is unlikely to stop spontaneously and emergency treatment must be initiated.
- $t_2$ (30 minutes): The time beyond which prolonged ictal activity causes irreversible neuronal apoptosis, excitotoxicity, and permanent pharmacoresistance.
Landmark Evidence For Second-Line Therapy
Historically, intravenous phenytoin or fosphenytoin was the mandatory second-line therapy after benzodiazepine failure. Three landmark randomized controlled trials published in The Lancet and NEJM shifted international and Indian guidelines:
1. The ESETT Trial (NEJM 2019)
- Established Status Epilepticus Treatment Trial; multi-center, randomized, blinded adaptive trial enrolling children (aged $\ge 2$ years) and adults.
- Compared Levetiracetam ($60\text{ mg/kg}$, max 4500 mg) vs Fosphenytoin ($20\text{ mg PE/kg}$, max 1500 mg PE) vs Sodium Valproate ($40\text{ mg/kg}$, max 3000 mg) infused over 10 minutes.
- Findings: Seizure cessation and alertness at 60 minutes occurred in 47% with levetiracetam, 45% with fosphenytoin, and 46% with valproate (true equiefficacy across all three arms).
- Levetiracetam and valproate demonstrated lower rates of hypotension, cardiac arrhythmias, and respiratory depression requiring endotracheal intubation compared to fosphenytoin.
2. The EcLiPSE Trial (Lancet 2019)
- Pragmatic UK open-label RCT in children aged 6 months to 18 years with convulsive status persisting after first-line benzodiazepines.
- Compared IV Levetiracetam ($40\text{ mg/kg}$ over 5 minutes) vs IV Phenytoin ($20\text{ mg/kg}$ over 20 minutes).
- Findings: Seizure termination occurred in 70% with levetiracetam and 64% with phenytoin. Median time to achieve seizure cessation was 35 minutes with levetiracetam vs 45 minutes with phenytoin.
- Levetiracetam was significantly faster to prepare and infuse, with zero purple glove syndrome or tissue necrosis.
3. The ConSEPT Trial (Lancet 2019)
- Australian and New Zealand pediatric emergency multicenter RCT.
- Compared IV levetiracetam ($40\text{ mg/kg}$) vs IV phenytoin ($20\text{ mg/kg}$) for benzodiazepine-refractory convulsive SE.
- Findings: Clinical seizure cessation at 5 minutes post-infusion was 50% in the levetiracetam group vs 60% in the phenytoin group ($p=0.19$, non-inferior).
- When a second non-benzodiazepine ASM was needed, administering levetiracetam followed by phenytoin (or vice versa) achieved clinical cessation in 75% of children.
Stepwise Emergency Pharmacological Protocol
flowchart TD
A["<b>0–5 min: Stabilization & Assessment</b><br>• Airway, 100% O2, recovery position, check bedside glucose<br>• Secure IV access; if hypoglycemic: 2 mL/kg 10% dextrose IV"] --> B{"Seizure persists > 5 min"}
B --> C["<b>5–15 min: First-Line Benzodiazepine (Max 2 Doses)</b><br>• IV access: IV Lorazepam 0.1 mg/kg (max 4 mg) over 1–2 min<br>• No IV access: IN / Buccal Midazolam 0.2 mg/kg (max 10 mg) or IM Midazolam 0.2 mg/kg<br>• If persists after 5–10 min: Repeat ONE dose only"]
C --> D{"Seizure persists > 10–15 min"}
D --> E["<b>15–30 min: Second-Line Non-Benzodiazepine ASM</b><br>• 1st choice: IV Levetiracetam 60 mg/kg (max 4500 mg) over 5 min<br>• 2nd choice: IV Sodium Valproate 40 mg/kg (max 3000 mg) over 10 min<br>• Alternative: IV Fosphenytoin 20 mg PE/kg (max 1500 mg PE) over 10 min"]
E --> F{"Seizure persists > 30 min"}
F --> G["<b>> 30 min: Refractory Status Epilepticus (RSE)</b><br>• Secure airway (Intubation) and transfer to PICU<br>• Continuous IV infusion: Midazolam (load 0.2 mg/kg, then 1–5 mcg/kg/min)<br> OR Propofol (1–2 mg/kg load) OR Ketamine (load 1–2 mg/kg)<br>• Urgent continuous EEG (cEEG) monitoring"]
Refractory And Super-Refractory Status Epilepticus
- Refractory Status Epilepticus (RSE): Seizures continuing despite adequate doses of a benzodiazepine and at least one second-line non-benzodiazepine ASM.
- Super-Refractory Status Epilepticus (SRSE): Status epilepticus continuing or recurring $\ge 24\text{ hours}$ after initiating continuous anesthetic infusions, including cases where seizures recur upon weaning anesthetics.
- Early Ketamine Administration: Prolonged seizures cause endocytosis and loss of inhibitory synaptic $GABA_A$ receptors alongside upregulation of excitatory NMDA receptors. Ketamine blocks NMDA receptors, restoring antiepileptic efficacy when GABAergic agents fail.
- Continuous EEG (cEEG) Monitoring: Indicated immediately upon PICU admission; up to 30% to 40% of children with controlled motor convulsive status continue to have Non-Convulsive Status Epilepticus (NCSE).
- NORSE & FIRES: New-Onset Refractory Status Epilepticus (NORSE) and Febrile Infection-Related Epilepsy Syndrome (FIRES) require early initiation of immunomodulatory therapy (high-dose methylprednisolone, IVIG, or Anakinra/IL-1 receptor antagonist) within 48 to 72 hours of onset.